NASDAQ:ACAD

ACADIA Pharmaceuticals Stock Forecast, Price & News

$16.71
+0.01 (+0.06 %)
(As of 09/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.16
$16.88
50-Day Range
$15.78
$24.26
52-Week Range
$15.68
$57.46
Volume1.33 million shs
Average Volume1.86 million shs
Market Capitalization$2.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.66
30 days | 90 days | 365 days | Advanced Chart
Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


ACADIA Pharmaceuticals logo

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.63 out of 5 stars

Medical Sector

53rd out of 1,352 stocks

Pharmaceutical Preparations Industry

25th out of 665 stocks

Analyst Opinion: 4.2Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

Is ACADIA Pharmaceuticals a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 12 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ACADIA Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View analyst ratings for ACADIA Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than ACADIA Pharmaceuticals?

Wall Street analysts have given ACADIA Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ACADIA Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for ACADIA Pharmaceuticals
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings results on Tuesday, August, 3rd. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.03. The biopharmaceutical company earned $115.22 million during the quarter, compared to the consensus estimate of $124.94 million. ACADIA Pharmaceuticals had a negative net margin of 56.49% and a negative trailing twelve-month return on equity of 43.11%. The firm's quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.27) EPS.
View ACADIA Pharmaceuticals' earnings history
.

How has ACADIA Pharmaceuticals' stock been impacted by COVID-19?

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACAD shares have decreased by 54.7% and is now trading at $16.71.
View which stocks have been most impacted by COVID-19
.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $480 million-$515 million, compared to the consensus revenue estimate of $521.79 million.

What price target have analysts set for ACAD?

18 equities research analysts have issued 12 month target prices for ACADIA Pharmaceuticals' shares. Their forecasts range from $18.00 to $57.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $28.73 in the next twelve months. This suggests a possible upside of 71.9% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the following people:

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among ACADIA Pharmaceuticals' employees.

Who are some of ACADIA Pharmaceuticals' key competitors?

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (9.65%), Vanguard Group Inc. (7.17%), Price T Rowe Associates Inc. MD (6.35%), BlackRock Inc. (6.33%), State Street Corp (2.47%) and First Trust Advisors LP (1.82%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals
.

Which major investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Deutsche Bank AG, Goldman Sachs Group Inc., Susquehanna International Group LLP, Bank of America Corp DE, Nuveen Asset Management LLC, Group One Trading L.P., and Citadel Advisors LLC. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, Michael J Yang, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Price T Rowe Associates Inc. MD, First Trust Advisors LP, JPMorgan Chase & Co., Ikarian Capital LLC, State Street Corp, Northern Trust Corp, and Vanguard Group Inc..
View insider buying and selling activity for ACADIA Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $16.71.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals has a market capitalization of $2.68 billion and generates $441.76 million in revenue each year. The biopharmaceutical company earns $-281,580,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals employs 601 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

Where are ACADIA Pharmaceuticals' headquarters?

ACADIA Pharmaceuticals is headquartered at 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at (858) 558-2871 or via email at [email protected].


This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.